Meta AnalysisID 6839
舒肝解郁胶囊联合艾司西酞普兰治疗老年抑郁症的临床有效性和安全性：一项系统评价和Meta分析
CRD42023440270
Shugan Jieyu Capsule is the first Chinese patent medicine approved for the treatment of mild and moderate Uniphase depression. It can improve the symptoms of depression caused by liver stagnation and spleen deficiency, a
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6839
- Evidence Id
- 15397
- Core Evidence Id
- 15397
- Source Meta Analysis Id
- 6838
- Herb2 Meta Analysis Id
- HBMA006838
- Crd Id
- CRD42023440270
- Title
- Clinical Efficacy and Safety of Shugan Jieyu Capsule Combined with Escitalopram in the Treatment of Senile Depression: A Systematic Review and Meta-analysis
- Review Question
- Shugan Jieyu Capsule is the first Chinese patent medicine approved for the treatment of mild and moderate Uniphase depression. It can improve the symptoms of depression caused by liver stagnation and spleen deficiency, and its curative effect mainly shows that it can improve depression, anxiety, insomnia, and other aspects, with fewer adverse reactions and good compliance. In the treatment of acute-stage of senile depression, escitalopram is well tolerated, but there is no significant difference compared with placebo. Escitalopram has been widely used in the treatment of elderly patients with depression in recent years because it has the best anti-5-HT reuptake effect. However, the effect of the drug after use is relatively slow, especially in the early stage of the most critical treatment of depression. Given the deficiency of escitalopram, the combination of drugs can be used to improve the speed of drug action. In this paper, clinical randomized controlled trials on the intervention of Shugan Jieyu capsule combined with Escitalopram in geriatric depression were screened from multiple databases, aiming to evaluate the clinical value of the combined treatment of the two drugs in geriatric depression and provide new evidence for further research on the synergistic and antagonistic effects of integrated Chinese and Western medicine in clinical application, as reported below.
- Study Type Included
- RCTs of Shugan Jieyu capsule combined with Escitalopram for senile depression. Protocol, case reports, reviews, letters, cell experiments, animal experiments, and non-RCTs were included.
- Condition Being Studied
- Depression is a complex condition that exists at all ages, with many branches and different triggers. Clinical manifestations are often depressed mood, lack of interest in things, serious people have suicidal thoughts, especially in the elderly group, all aspects of its body function are declining, accompanied by depression treatment is extremely difficult, with high recurrence characteristics. Shugan Jieyu Capsule is the first Chinese patent medicine approved for the treatment of mild and moderate unipolar depression. Escitalopram is a highly selective serotonin reuptake inhibitor (SSRIs) that results in rapid improvement of depressive symptoms. The clinical studies on the treatment of senile depression with the combination of Shugan Jieyu Capsule have gradually increased, indicating that the combination of Shugan Jieyu capsule has gradually become a focus of clinical research in recent years。
- Participant
- Depression in old age. Patients with depression diagnosed according to the Chinese Diagnostic Classification System and diagnostic criteria [8] or consistent with the Tenth Revision of the International Statistical Classification of Diseases and Related Health Problems. Age ≥60 years old, regardless of ethnicity or gender; Did not take antidepressants before 2 weeks.
- Animal
- Human Disease Modelled
- Intervention
- Shugan Jieyu capsule combined with Escitalopram
- Comparator Control
- Escitalopram
- Main Outcome
- Total response rate. Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), serum 5-hydroxytryptamine (5-HT), adverse reactions.
- Outcome Measure
- Additional Outcome
- Not applicable.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Aged; Anxiety; Depression; Escitalopram; Humans; Liver; Nonprescription Drugs; Randomized Controlled Trials as Topic; Sleep Initiation and Maintenance Disorders; Spleen; Treatment Outcome
- Contact
- Congcong Yu [email protected]
- Organisational Affiliation
- Sichuan Integrative Medicine Hospital
- Funding Source
- Sichuan Science and Technology Department Grant number(s) State the funder, grant or award number and the date of award No. 2022YFS0446
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-06-28
- Registration Date
- 2023-07-10
- Anticipated Start Date
- 2023-05-01
- Anticipated Completion Date
- 2023-07-27
- Title Cn
- 舒肝解郁胶囊联合艾司西酞普兰治疗老年抑郁症的临床有效性和安全性：一项系统评价和Meta分析
- Title En
- Clinical Efficacy and Safety of Shugan Jieyu Capsule Combined with Escitalopram in the Treatment of Senile Depression: A Systematic Review and Meta-analysis
- Bilingual Status
- complete